India News
Under Donald Trump's leadership, the United States followed an 'America First' policy, which led to higher tariffs on products from other countries, resulting in significant changes in the trade sector. In the past, Trump imposed additional taxes on products from China, India, Mexico, and European countries. Now, he has decided to impose tariffs on pharma products and semiconductors. As a result, domestic stock market indices are experiencing massive losses. Pharma stocks, which showed gains in yesterday's trading session, have now slipped into losses. The main reason behind this is Trump's recent announcement.
Trump's statement about imposing tariffs on U.S. pharma products has led to a 4.2% decline in the Nifty Pharma index. During intraday trading, this index dropped to a low of 20,521 points. The U.S. is set to impose new taxes on pharma products manufactured in India, which may lead to losses for Indian pharma companies, according to financial experts. Due to Trump's recent comments, the pharma sector, which had remained stable the previous day, suddenly fell into losses. Major pharma companies, such as Aurobindo Pharma, Ipca Laboratories, Lupin, Biocon, Cipla, Divis Laboratories, Dr. Reddy's, and Sun Pharma, all saw significant declines.
With the U.S. frequently imposing tariffs on products from other countries, global trade relations are being impacted. Since India's pharma industry is the largest in the world, any imposition of higher taxes in the U.S. will likely have a huge effect on exports. According to financial experts, stability in pharma stocks is unlikely until the U.S. government officially announces this decision. However, whether this decline will have a long-term impact remains to be seen in the near future.
Advertisment
